Currently, a myriad of new treatment options of both dyslipidemia and inflammation in ASCVD is emerging, to mention the availability of RNA-based inhibitors of the hepatic synthesis of apoB-containing lipoproteins which could be administered even once a year (318). Here, APOB is linked to metabolic syndrome.